
Depending on the selected support process (classic or accelerated), candidates will have access to a more or less developed process. The classic process is detailed below. For the accelerated one (3 months), the process will be reduced to a single coaching session and a possible hearing by the International MATWIN Board.
MATWIN support is open throughout the year. Interested candidates (academic teams or start-ups) enroll in the program by submitting an application. The program is now open to European applicants if they can prove that they have collaboration with French partners (academic team or company).
Classic process stages (6 months):
Each stage of the process is selective. Only the best projects will ultimately have the opportunity to be presented to the MATWIN International Board.
Preselection pitches :
Once the application file has been submitted to MATWIN, the project is pre-selected for a pitch presentation before a multidisciplinary jury meeting in November.
The projects selected by the experts will then be submitted to the MATWIN International Board members (on the basis of the application dossier), who will be the ones deciding which projects can be included in the programme.
The written comments of the MATWIN Board members will be sent to all applicants by end of January.
On the basis of experts assessments, projects are invited or not to continue the process (coaching) for a possible presentation at the MATWIN International Board meeting at the end of the process. Projects are not competing against each other, only intrinsic value and development potential are taken into account.
The pre-selection pitches take place in Paris in November every year!
Composition of the pre-selection jury:Composition of the pre-selection jury:
election
Written International Board’s review :
The pre-selected candidates will have their file sent to the members of the International MATWIN Board. Candidates will receive written feedback from each member, real added value in understanding the strengths and weaknesses of the project.
Coaching sessions :
2 individual work sessions are organized to optimize projects’ structuring / industrial orientation and their presentation. Technology transfer offices are associated and included in the process. They are invited to participate in every working session organized by MATWIN next to the project leaders to benefit from the feedback.
Development Plan Review
Driven by innovation specialists and experts in preclinical and clinical development, this work session addresses the project’s background and allows to optimize its structure and industrial orientation. This session aims at supporting projects leaders in their valorization approach.
It takes place once a year in February/March in Paris with 2 coaches selected according to the type of project.
Training for the Board meeting audition
This second work session aims at preparing the project leader for his interview by the MATWIN International Board strengthened by the 1st session contributions. Experts speakers bring their expertise to optimize the project presentation. This session is in a real condition format (in English, in front of 2 cocaches) to reflect the MATWIN Board interview.
By end of the two coaching sessions, the coaches will select the 6 best projects that will be interviewed by the prestigious MATWIN Board.
It takes place once a year in April in Paris.

Dr. Avenard is Board member or adviser for several companies and Chief Executive Officer of G1J-IDF, a seed venture fund in Life Sciences. From 1997 to 2010, he served as Chief Operating Officer of BioAlliance Pharma SA (BIO – NYSE-EURONEXT) since he co-founded the company. From 1990 to 1997, Dr. Avenard served as Medical Director of Development in the Cassenne Laboratories division of Hoechst Marion Roussel (Sanofi-Aventis Pharma).From 1976 to 1990, Dr. Avenard held various positions with the National Blood Transfusion Center in Paris, including Medical Director of Bio-Transfusion (LFB), providing human plasma products. He has also served as a physician in hemobiology and blood transfusion at the Blood Center of Pitié-Salpétrière Hospital in Paris. Dr. Avenard received his MD as well as degrees in hematology and hemobiology & blood transfusion from the School of Medicine at the University of Paris V. He is currently member of the Biotech Working Group at LEEM (pharmaceutical French trade association). He is also expert for Research Tax Credit at the Ministry of Research.

- MD-PhD specialized in gastroenterology and oncology with 15 years’ experience in people management and healthcare product management.
- Hepato-Gastroenterologist in France during 15 years & member of French Gastro Intestinal Societies (SFED, FFCD)
- Always operating in Personalized/Precision Medicine landscape
- Experience in clinical development (early to late clinical development, Phase 0 to Phase IV), training and education
- Expertise on consulting activities: Medical & business strategies for oncology focused biotechnologies
- Executive MBA HEC Paris (Major: Services. Center for Services Leadership Arizona State School of Business; Phoenix, AZ)
- Keen on cutting-edge science
- Extensive European Oncology network
- Field and Marketing experience
- Great knowledge of targeted therapies in Oncology and Hematology
- Expertise in Diagnostic tools (Companion tests, biomarkers, Genomic)
- Leadership and entrepreneurial focused

Jean-Yves Bonnefoy is CEO of Anagenesis Biotechnologies since January 2014. He is also President of the Life Sciences Competitiveness Cluster, Alsace BioValley, Board member of biotech companies Anagenesis and SILABE and of the engineer school ESBS. He is a member of the scientific advisory board of iTeos Therapeutics and Centre de Recherche des Cordeliers. He is also member of the investment committee of the TTO, SATT Conectus. Before Anagenesis Biotechnologies he co-founded Transgene Spin-off, ElsaLys Biotech. He was for 8 years VP, R&D of Transgene SA. From 2002 to 2005, he launched and managed the Canceropole Lyon Rhône-Alpes. From 1992 to 2002, he headed the Centre d’immunologie Pierre Fabre. From 1998 to 2002, he was Director of the Immunology Department of the Glaxo-Wellcome Institute in Switzerland. From 1985 to 1987, he was scientist at the Research Centre of Schering-Plough in France. He is author and co-author of more than 200 publications and reviews (H-index 55-30-13). Jean-Yves holds a PhD in Immunology, a “Thèse 3ème cycle” in Biochemistry and followed the Senior Management Program of the London Business School, in the UK.

Executive and non-executive managerial, technical and scientific skills in highly innovative and technology oriented environments for international start-up and grown-up companies in the Life sciences (Medical Devices / Clinical Development / Medical Imaging), and IT areas:
- Research and Development, information technology and SW development expertise
- Medical Imaging for Drug Development and Patient Care
- Regulatory and Quality Assurance frameworks for Medical device, Drug Development and In-Vitro Diagnostics
- Information Systems
- Operations / Customer Services / Program Management
- Fund raising / IPO
- Corporate development, strategic partnerships
- Independent board member

Trained as a doctor, Marie-Pierre Chevalier has more than 20 years of experience in major international pharmaceutical groups in various positions in clinical development, business development, KOLs management in different therapeutic fields such as oncology, rare diseases, neurodegenerative diseases, chronic inflammatory diseases, etc.
For the past 10 years, she has successfully led the open-innovation entity of Pfizer France, creating numerous collaborations between the group’s global R&D and academic or Biotechs teams.
More recently, she initiated the organization’s digital transformation with the launch of two startup acceleration programs.
Very involved in the health innovation ecosystem, she has been a member of several life science investment funds such as the InnoBio Fund and the Autonomous Patient Fund.
She also served on the selection committee of the iPEPs incubator of the Brain and Marrow Institute at the Hôpital de La Pitié-Salpêtrière in Paris.

Dr. Thérèse Croughs has more than 20 years of experience in clinical development and regulatory affairs. She has worked in companies of varying sizes and clinical stages of development in the pharmaceutical and biotech industries in Europe, North America and Asia.
Thérèse Croughs began her career in the pharmaceutical industry at Bayer, where she worked on protocol definition and the conduct of several clinical trials, as well as the registration of several products, including r-FVIII in hemophilia. A. After 10 years at Bayer, Thérèse joined the Novo Nordisk team as International Medical Advisor for the clinical development in Europe of r-FVIIa for the treatment of severe bleeds. Thérèse Croughs continued her career at BioAlliance Pharma, where she held the position of Director of the Adhesive Technology and New Business Unit and Director of European Regulatory Affairs. More recently and for more than 6 years, Thérèse Croughs was the Medical Director of Cytheris where she was in charge of regulatory strategy and international development of the IL-7 immunotherapy program (r-hIL-7, a factor growth of the immune system). Thérèse Croughs is a graduate of the Faculty of Medicine of the Catholic University of Louvain – Brussels, Belgium. Since 2015, she is Chef Medical Officer for NEOVACS.

Dr Joël Crouzet is the CEO of Ermium Therapeutics. He has more than 30 years of experience in the Biotech and the Pharma industry. He has been the cofounder and CEO of InnaVirVax, a French biotech that developed a therapy for HIV infection up to phase 2 clinical trial. Joël has had various positions in several biotech companies (Genetica, AP cells, Neurotech and Alfact Innovation) and in the Pharma (Rhone-Poulenc Rorer now part of Sanofi Aventis) and has been involved actively in 5 different drug candidates studied in the clinic. Scientific by training, Joël is a co-author of more than 60 peer reviewed publications.

Jean-Marc HERBERT has more than 30 years of industrial experience in pharmaceutical R & D at international scientific and managerial positions.
Jean-Marc was Senior Vice President, Head of Discovery at Sanofi. Jean-Marc has been instrumental in the discovery and development of more than 70 drug candidates including marketed products such as Plavix® and Arixtra®. He holds an engineering degree in Biochemical Engineering and a PhD in Cellular and Molecular Biology from the University of Clermont-Ferrand. He did his Ph.D. in Cell Biology and Biochemistry at the Clinical Research Center in London (UK).
Today Jean-Marc is President of ARKELY-Consulting, a consulting company in translational research for the discovery and development of innovative medicines.

– Oncology – Hematology Business Unit Manager in France ( Marketing and Sales with 250 people and 960 Mio € turnover )
– Global experience as Life Cycle Leader (LCL) acting as “General Manager “ of a biologic brand / Franchise
– Expertise in the fields of Marketing, Sales and Management
– Extensive knowledge of the hospital field and different therapeutic areas (Oncology , Immuno oncology ,Hematology, Genomic Profiling ,Hemophilia, Neurology(MS), rheumatology, Auto Immune disease, anemia, transplantation, nephrology, infectious diseases…) High level of involvement in the commercial approach (hospital tenders)

– More than 20 years experience in Strategy, Operations, Business Development in Pharma and Biotechs.
– Project coordination and development as Project director with Sanofi
– Set-up of a Biotech-like research insitute, from Business Model elaboration up to effective implementation
– Acting COO, CBO and Head BD
– Biotech consultancy: early stage projects positioning, market potentials, Operations, Business, acting CBO, acting COO, transactions, negotiations, alliance and key partnerships management, commercial license negotiation and management….
– Expertise in rare disease, gene therapy, oncology, diabetes and cardiovascular drug development from R&D to market.
– Member of Executive Committee in charge of Operations and Business Development in Biotechs.
MATWIN Board interview :
Selected applicants submit their projects in front of the MATWIN International Board. This unique in Europe committee auditions the projects and labels those with the highest industrial development transfer potential. This committee’s feedback represents a significant added value for the project development.
After presenting to the Board, candidates may initiate discussions with certain members, or any other actor of the ecosystem (Biotechs, investors …) likely to collaborate on the development of the project. Auditioned projects will be monitored by the Board.